BioPharmSignal logoBioPharmSignal

Biotech News

Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences

Gain Therapeutics (GANX)Gain TherapeuticsConference / presentation

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of two late-breaking posters at the 31 st IAPRD World Congress on Parkinson’s Disease and Related Disorders as well as a poster at Neuroscience 2026.

Related news

GANXGain Therapeutics2026-09-29 21:50 EST

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

GANXGain Therapeutics2026-09-17 11:00 EST

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference

KTTAPasithea Therapeutics2026-09-03 20:05 EST

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

ALKSAlkermes plc2026-11-03 21:00 EST

Alkermes to Present at Upcoming Investor Conferences

VYGRVoyager Therapeutics2026-10-27 12:01 EST

Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026

NBIXNeurocrine Biosciences2026-09-02 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

HRMYHarmony Biosciences2026-09-03 12:05 EST

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

CGTXCognition Therapeutics2026-09-08 11:30 EST

Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference

ANLAdlai Nortye Ltd.2026-10-27 20:05 EST

Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium

NERVMinerva Neuroscience2026-10-29 11:00 EST

Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London

View all latest news

Gain Therapeutics

Allosteric Small-Molecule Platform Gain Therapeutics uses its Magellan discovery platform to identify allosteric small molecules that restore the function of disease-associated proteins. Its lead efforts focus on neurodegenerative disorders. GT-02287 GT-02287 is an oral, brain-penetrant modulator of glucocerebrosidase being developed for...

Recent company news

GANXGain Therapeutics2026-11-05 12:00 EST

Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences

GANXGain Therapeutics2026-10-08 11:00 EST

Gain Therapeutics to Attend the 2026 Maxim Growth Summit

GANXGain Therapeutics2026-10-01 13:28 EST

Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration

GANXGain Therapeutics2026-09-29 21:50 EST

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

GANXGain Therapeutics2026-09-17 11:00 EST

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference

Stock data

Close
0.96 USD
Market cap
78.06M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States